BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...Phase II dose this quarter.Aisling’s Elms and Venrock’s...
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

...By Virginia Li, Associate Editor With its latest $450 million fund, Venrock has eschewed the broader...
...first-in-class therapies, genomics platforms and healthcare IT. According to the firm’s Bryan Roberts, about half of Venrock...
...LianBio and engineered microbe developer Federation Bio Inc. While more than a dozen VCs raised record funds last year, Venrock’s last...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...and commercial success, including a handful of ten-figure takeouts.The series B round was led by Venrock...
...translational medicine, and Eric Bischoff as SVP of development and operations.Bong Koh, the lead investor from Venrock...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury at the time. RA Capital, Venrock...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...Farallon Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...companies. A crossover syndicate is investing $91 million into the union; leader Fairmount Funds Management joins Venrock...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...NASDAQ:MYOK) and BridgeBio Pharma Inc. (NASDAQ:BBIO).RA Capital, Venrock...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...which saw participation from seed investors including Venrock...
...VP of BD at 23andMe Inc. She succeeds Venrock...
...enabling application beyond Clostridium difficile infections as a driver of Venrock’s...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

...if the general markets are volatile,” she said. Venrock’s...
Items per page:
1 - 10 of 455
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...Phase II dose this quarter.Aisling’s Elms and Venrock’s...
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

...By Virginia Li, Associate Editor With its latest $450 million fund, Venrock has eschewed the broader...
...first-in-class therapies, genomics platforms and healthcare IT. According to the firm’s Bryan Roberts, about half of Venrock...
...LianBio and engineered microbe developer Federation Bio Inc. While more than a dozen VCs raised record funds last year, Venrock’s last...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...and commercial success, including a handful of ten-figure takeouts.The series B round was led by Venrock...
...translational medicine, and Eric Bischoff as SVP of development and operations.Bong Koh, the lead investor from Venrock...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury at the time. RA Capital, Venrock...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...Farallon Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...companies. A crossover syndicate is investing $91 million into the union; leader Fairmount Funds Management joins Venrock...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...NASDAQ:MYOK) and BridgeBio Pharma Inc. (NASDAQ:BBIO).RA Capital, Venrock...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...which saw participation from seed investors including Venrock...
...VP of BD at 23andMe Inc. She succeeds Venrock...
...enabling application beyond Clostridium difficile infections as a driver of Venrock’s...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

...if the general markets are volatile,” she said. Venrock’s...
Items per page:
1 - 10 of 455